✦ LIBER ✦

Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin Versus doxorubicin and cyclophosphamide (a phase III trial of the gynecologic oncology group)

✍ Scribed by Hyman B. Muss; Brian Bundy; Philip J. Disaia; Howard D. Homesley; Wesley C. Fowler Jr.; William Creasman; Edgardo Yordan

Publisher: John Wiley and Sons
Year: 1985
Tongue: English
Weight: 524 KB
Volume: 55
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19850415)55:8<1648::aid-cncr2820550806>3.0.co;2-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized trial of cyclophosphamide a

A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A gynecologic oncology group study

✍ George Omura; John A. Blessing; Clarence E. Ehrlich; Alexander Miller; Edgardo Y 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 593 KB

Phase III trial of cyclophosphamide vers

Phase III trial of cyclophosphamide versus cyclophosphamide, doxorubicin, and methotrexate in hormone-refractory prostatic cancer: A hoosier oncology group study

✍ Scott Saxman; Rafat Ansari; Ray Drasga; Michael Miller; Ben Wheeler; John McClea 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 489 KB 👁 2 views

A prospective randomized trial of doxoru

A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer

✍ Massimo Lopez; Alma Contegiacomo; Patrizia Vici; Concetta Dello Ioio; Luigi Di L 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 481 KB 👁 2 views

Seventy-six patients with advanced breast cancer were entered into the current study. They were randomized to receive either idarubicin (IDA) 45 mg/m2 orally or doxorubicin (DX) 75 mg/m2 intravenously (IV), both drugs being administered every 3 weeks. Among 37 evaluable patients who received DX trea

A prospective, randomized phase III tria

A prospective, randomized phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma

✍ Cesar Blajman; L. Balbiani; J. Block; F. Coppola; R. Chacon; L. Fein; S. Bonicat 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 2 views

## Background: A prospective, multicenter, randomized, phase iii trial comparing the efficacy of combination chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide (fac) with a combination of vinorelbine and doxorubicin (na) in the treatment of patients with advanced breast carcinoma w

Vincristine, doxorubicin, and cyclophosp

Vincristine, doxorubicin, and cyclophosphamide versus low-dose intravenous cyclophosphamide, methotrexate, and 5-fluorouracil in advanced breast cancer. A randomized trial of the piedmont oncology association

✍ Hyman B. Muss; Frederick Richards II; Don V. Jackson; M. Robert Cooper; Douglas 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 538 KB

Phase III trial of methotrexate, vinblas

Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium : A trial of the Eastern Cooperative Oncology Group

✍ Robert Dreicer; Judith Manola; Bruce J. Roth; William A. See; Steven Kuross; Mar 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB 👁 3 views

## Abstract ## BACKGROUND The regimens of carboplatin plus paclitaxel (CP) and methotrexate, vinblastine, doxorubicin, and cisplatin (M‐VAC) were compared in patients with advanced urothelial carcinoma. ## METHODS Patients with metastatic urothelial carcinoma were randomized to receive either CP